Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Bone Marrow and Peripheral Blood Chimerism

Outcome Description:

Percent of donor and host cells in peripheral blood and bone marrow will be measured by short tandem repeat (STR) testing and/or standard cytogenetic testing.

Outcome Time Frame:

30 days post-transplant

Safety Issue:

No

Principal Investigator

Jeffrey W. Andrey, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Scripps Clinic Medical Group

Authority:

United States: Institutional Review Board

Study ID:

HSC-03-2329

NCT ID:

NCT01364363

Start Date:

March 2005

Completion Date:

January 2023

Related Keywords:

• Severe Aplastic Anemia
• Paroxysmal Nocturnal Hemoglobinuria
• Acute Myelogenous Leukemia
• Acute Lymphoblastic Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Syndromes
• Chronic Myelogenous Leukemia
• Hodgkin's Lymphoma
• Non-Hodgkin's Lymphoma
• Multiple Myeloma
• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma
• Large Granulocytic Leukemia
• Transplant
• Allogeneic
• Allogeneic transplant
• Unrelated donor transplant
• MUD
• HSCT
• Stem cell transplant
• Anemia
• Anemia, Aplastic
• Hemoglobinuria
• Hodgkin Disease
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Leukemia, Myeloid, Acute
• Leukemia, Myeloid
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Lymphoma
• Lymphoma, Non-Hodgkin
• Hemoglobinuria, Paroxysmal
• Multiple Myeloma
• Neoplasms, Plasma Cell
• Myelodysplastic Syndromes
• Preleukemia
• Myeloproliferative Disorders